Form 8-K - Current report:
SEC Accession No. 0001628280-26-019878
Filing Date
2026-03-19
Accepted
2026-03-19 17:19:46
Documents
11
Period of Report
2026-03-17
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K skye-20260317.htm   iXBRL 8-K 29646
  Complete submission text file 0001628280-26-019878.txt   136747

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT skye-20260317.xsd EX-101.SCH 1804
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT skye-20260317_lab.xml EX-101.LAB 20073
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT skye-20260317_pre.xml EX-101.PRE 11528
15 EXTRACTED XBRL INSTANCE DOCUMENT skye-20260317_htm.xml XML 2731
Mailing Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130
Business Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266
Skye Bioscience, Inc. (Filer) CIK: 0001516551 (see all company filings)

EIN.: 450692882 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42009 | Film No.: 26775239
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)